An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4893-4901

  Kalli, Kimberly R ^a   Krco, Christopher J ^b   Hartmann, Lynn C ^a   Goodman, Karin ^a   Maurer, Matthew J ^a   Yu, Chao ^b   Johnson, Elliot M ^b   Erskine, Courtney L ^b   Disis, Mary L ^c   Wettstein, Peter J ^b   Fikes, John D ^d   Beebe, Melanie ^d   Ishioka, Glenn ^d   Knutson, Keith L ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Center for Translational Medicine in Women's Health   (United States)

^d Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DR1 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 2; PEPTIDE FRAGMENT;

ADULT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HLA-DR1 ANTIGEN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 49649084295     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6726     Document Type: Article

References (57)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
2. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243-51.
3. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
4. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000; 164:562-5.
5. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000;20:17-56.
6. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-204.
7. Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol Lett 2000;74:75-9.
8. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
9. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188: 2357-68.
10. Fallarino F, Grohmann U, Bianchi R, Vacca C, Fioretti MC, Puccetti P. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol 2000;165:5495-501.
11. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002;8:1014-8.
12. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
13. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
14. Hwang ML, Lukens JR, Bullock TN. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol 2007;179:5829-38.
15. Busund LT, Richardsen E, Busund R, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005;58:361-6.
16. Tennant MK TJ, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996;81:411-20.
17. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004;10:1796-806.
18. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 1998;8:473-9.
19. Gebauer G, Jager W, Lang N. mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res 1998;18:1191-5.
20. Lancaster JM, Sayer RA, Blanchette C, et al. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer 2006;16:1529-35.
21. Lee EJ, Mircean C, Shmulevich I, et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005;4:7.
22. Olchovsky D, Shimon I, Goldberg I, et al. Elevated insulin-like growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion. Acta Oncologica (Stockholm Sweden) 2002;41:182-7.
23. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol 2006;19:1149-56.
24. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997;8:45-62.
25. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
26. Hoeflich A, Reisinger R, Lahm H, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001;61:8601-10.
27. Knutson KL, Krco C, Goodman K, et al. T cell immunity to the folate receptor a is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24: 4254-61.
28. Dzuris JL, Sidney J, Appella E, Chesnut RW, Watkins DI, Sette A. Conserved MHC class I peptide binding motif between humans and rhesus macaques. J Immunol 2000;164:283-91.
29. Sette A, Buus S, Appella E, et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A 1989;86:3296-300.
30. Sette A, Buus S, Colon S, Miles C, Grey HM. Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol 1989;142:35-40.
31. Disis ML, Grabstein KH, Sleath PR, MA C. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
32. Disis ML, Dela Rosa C, Goodell V, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 2005;308:13-8.
33. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160: 3363-73.
34. Sidney J, Southwood S, Oseroff C, del Guercio MF, Grey HM, Sette A. Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol 1998;18:18.3.2-.3.9.
35. Chhieng DC, Rodriguez-Burford C, Talley LI, et al. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum Pathol 2003;34:1016-21.
36. Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-83.
37. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8: 3219-25.
38. Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol 2006; 176:5093-9.
39. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007;13: 5133-43.
40. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
41. Marsh GE, Parham P, Barber LD. The HLA facts book. San Diego: Academic Press; 2000.
42. Wilson CC, Palmer B, Southwood S, et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 2001;75: 4195-207.
43. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006;15:718-27.
44. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997;64:189-95.
45. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
46. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
47. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80.
48. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-5.
49. Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006;25:533-43.
50. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol 1993; 11:729-66.
51. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the her-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
52. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105:2132-4.
53. Finn OJ. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 2006;36:73-82.
54. Keilholz U. Antigen-specific cancer vaccines. Recent Results Cancer Res 2007;176:213-8.
55. Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit Rev Immunol 2001;21:263-73.
56. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
57. Hamdi H, Godot V, Maillot MC, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood 2007;110:211-9.